Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- Biomedicine (1)
- Biotechnology (1)
- Colleges and universities (1)
- De minimis economic injuries (1)
- Drugs (1)
-
- Economics (1)
- Experimental purpose doctrine (1)
- Federal Circuit (1)
- Food and Drug Law (1)
- Hatch-Waxman Act (1)
- Health Law and Policy (1)
- Integra Lifesciences I Ltd. v. Merck KGaA (1)
- Intellectual Property Law (1)
- International Trade (1)
- Law and Economics (1)
- Law and Society (1)
- Madey v. Duke University (1)
- Patent infringement (1)
- Patent law (1)
- Pharmaceuticals (1)
- Politics (1)
- Research and development (1)
- Safe harbors (1)
- Science and Technology (1)
- Trade Regulation (1)
- Publication Type
Articles 1 - 2 of 2
Full-Text Articles in Food and Drug Law
The Experimental Purpose Doctrine And Biomedical Research, Tao Huang
The Experimental Purpose Doctrine And Biomedical Research, Tao Huang
Michigan Telecommunications & Technology Law Review
The experimental use doctrine is a common law rule in patent law that until a few years ago excused accused infringers who made and used patented products or processes on the basis of an experimental, educational, or nonprofit purpose when there was de minimis economic injury to the patent owner and de minimis economic gain to the infringer. While the application of the experimental purpose doctrine was always narrow, two recent Federal Circuit decisions indicate that there is not much left under its aegis. In Madey v. Duke University, the Federal Circuit strictly limited the application of the experimental purpose …
Modern Bootlegging And The Prohibition On Fair Prices: Last Call For The Repeal Of Pharmaceutical Price Gouging, Luke W. Cleland
Modern Bootlegging And The Prohibition On Fair Prices: Last Call For The Repeal Of Pharmaceutical Price Gouging, Luke W. Cleland
ExpressO
This article discusses the recent passage of the Medicare Prescription Drug, Modernization and Improvement Act of 2003, and the executive and judicial decisions affecting the ability of the general public to access foreign pharmaceutical markets. The article examines the recent actions taken by the U.S. government, explore various state movements within the United States aimed at reducing pharmaceutical drug prices, outline the process of pharmaceutical drug prices in foreign countries, and advocate for a workable integration of all available mechanisms to feasibly reduce prescription drug prices for the benefit of both U.S. consumers and U.S. drug companies. As avenues to …